Ftse Mib
34.339,32
0,55%
DAX
18.686,60
1,07%
S&P 500
5.214,08
0,51%
NASDAQ
16.346,26
0,27%
Bitcoin
62.946,85
-0,16%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Imunon Inc (IMNN) Imunon Inc (IMNN) Notizie

Imunon Inc

IMNN
1,51
0,01 (0,67%)
10 Mag 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
08/5/202414:15EDGAR2Form 8-K - Current report
08/5/202414:00GLOBEIMUNON Appoints Director Dr. Stacy R. Lindborg as President..
06/5/202417:00GLOBEIMUNON to Hold First Quarter 2024 Financial Results and..
18/4/202414:30GLOBEIMUNON’s IND Application Cleared to Begin Human Testing of..
11/4/202414:00GLOBEIMUNON Reports Compliance with Nasdaq Listing Requirements
28/3/202413:00GLOBEIMUNON Reports 2023 Financial Results and Provides Business..
25/3/202413:30GLOBEIMUNON Receives $1.3 Million from Sale of its New Jersey Net..
21/3/202422:00GLOBEIMUNON to Hold 2023 Financial Results and Business Update..
13/3/202413:00GLOBEIMUNON Files IND Application to Begin Human Testing of..
12/3/202422:00GLOBEIMUNON Announces Leadership Change
29/2/202414:30GLOBEIndependent Lab Confirms Immunogenicity and Protection with..
27/2/202414:30GLOBEMemorial Sloan Kettering Cancer Center Now Enrolling..
22/2/202414:00GLOBEIMNN-101 Preclinical Data in SARS CoV-2 Published in..
09/2/202422:09EDGAR2Form S-1/A - General form for registration of securities..
29/12/202322:30EDGAR2Form 8-K - Current report
20/12/202323:15EDGAR2Form S-1 - General form for registration of securities under..
11/12/202322:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/12/202322:05EDGAR2Form 3 - Initial statement of beneficial ownership of..
11/12/202314:35EDGAR2Form 8-K - Current report
11/12/202314:30GLOBEIMUNON Appoints Dr. Sebastien Hazard as Chief Medical..
14/11/202315:00GLOBEIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
14/11/202314:00GLOBEIMUNON Reports Third Quarter 2023 Financial Results and..
07/11/202314:30GLOBEIMUNON to Hold Third Quarter 2023 Financial Results and..
23/10/202314:30GLOBEIMUNON’s Chief Science Officer to Present at the 3rd..
19/10/202314:30GLOBEIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel..
18/10/202314:30GLOBEIMUNON Announces First Patient enrolled in Phase 1/2..
06/10/202314:30GLOBEIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory..
28/9/202314:30GLOBEIMUNON Reports Interim Progression-Free Survival and Overall..
26/9/202314:30GLOBEIMUNON Releases Enterprise Video Highlighting the Company’s..
13/9/202314:30GLOBEIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at..
07/9/202322:30GLOBEIMUNON to Host Virtual R&D Day on September 14th Beginning..
05/9/202314:30GLOBEIMUNON to Participate in the H.C. Wainwright Global..
24/8/202322:05GLOBEIMUNON Enters into CRADA for Preclinical Studies of PlaCCine..
14/8/202314:30GLOBEIMUNON Expands Scientific Advisory Board with the Addition..
10/8/202314:00GLOBEIMUNON Reports Second Quarter 2023 Financial Results and..
07/8/202314:30GLOBEPreclinical Data Showing Strong Immunogenicity and..
03/8/202314:30GLOBEIMUNON to Hold Second Quarter 2023 Financial Results and..
27/6/202318:00GLOBEIMUNON Unveils New Manufacturing Capabilities at..
26/6/202323:00GLOBEImunon Reports Inducement Grants under NASDQ Listing Rule..
12/6/202314:30GLOBEIMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy..
08/6/202314:30GLOBEIMUNON’s CEO Presents Business Overview to Investors and..
30/5/202314:00GLOBEIMUNON Presents PlaCCine Preclinical Data at the 2023..
11/5/202314:00GLOBEIMUNON Reports First Quarter 2023 Financial Results and..
Apertura: 1,53 Min: 1,43 Max: 1,57
Chiusura: 1,50

La tua Cronologia

NASDAQ
IMNN
Imunon
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network